The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1

Journal of Viral Hepatitis

Volumn 22, Issue 3, 2015, Pages 254-262

  Oze, T ^a   Hiramatsu, N ^a   Yakushijin, T ^a   Yamada, R ^a   Harada, N ^a   Morishita, N ^a   Oshita, M ^b   Mita, E ^c   Ito, T ^d   Inui, Y ^e   Inada, M ^f   Tamura, S ^g   Yoshihara, H ^h   Imai, Y ⁱ   Kato, M ^j   Miyagi, T ^a   Yoshida, Y ^a   Tatsumi, T ^a   Kasahara, A ^k   Hayashi, N ^l   Takehara, T ^a   more..

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA POLICE HOSPITAL   (Japan)

^c OSAKA NATIONAL HOSPITAL   (Japan)

^d OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^e Hyogo Prefectural Nishinomiya Hospital   (Japan)

^f TOYONAKA MUNICIPAL HOSPITAL   (Japan)

^g Minoh City Hospital   (Japan)

^h OSAKA ROSAI HOSPITAL   (Japan)

ⁱ IKEDA MUNICIPAL HOSPITAL   (Japan)

^j National Hospital Organizaton Minami Wakayama Medical Center   (Japan)

^k OSAKA UNIVERSITY HOSPITAL   (Japan)

^l KANSAI ROSAI HOSPITAL   (Japan)

more..

Author keywords

chronic hepatitis C; discontinuation rate; drug adherence; older patients; telaprevir with pegylated interferon and ribavirin

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; OLIGOPEPTIDE; RECOMBINANT PROTEIN;

ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; JAPANESE (PEOPLE); KIDNEY DISEASE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NEUTROPHIL COUNT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; BIOPSY; CLINICAL TRIAL; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RISK FACTOR; VIROLOGY;

AGED; ANTIVIRAL AGENTS; BIOPSY; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84923204718     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12289     Document Type: Article

References (19)

1. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB,. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444.
2. McHutchison JG, Everson GT, Gordon SC, et al,. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
3. Hezode C, Forestier N, Dusheiko G, et al,. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
4. McHutchison JG, Manns MP, Muir AJ, et al,. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303.
5. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
6. Sherman KE, Flamm SL, Afdhal NH, et al,. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024.
7. Zeuzem S, Andreone P, Pol S, et al,. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
8. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N,. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84.
9. Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H,. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat 2012; 19: 134-142.
10. Mauss S, Hueppe D, Alshuth U,. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology 2014; 59: 46-48.
11. Fukuda K, Imai Y, Hiramatsu N, et al,. Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C. Hepatol Res In press; doi: 10.1111/hepr.12229
12. Reesink HW, Zeuzem S, Weegink CJ, et al,. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131: 997-1002.
13. Suzuki F, Akuta N, Suzuki Y, et al,. Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks. Hepatol Res 2009; 39: 1056-1063.
14. Oze T, Hiramatsu N, Yakushijin T, et al,. The prospective randomised study on telaprevir at 1500 mg or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1. J Gastroenterol 2014; In press; doi: 10.1007/s00535-014-0965-8
15. Bedossa P, Poynard T,. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.
16. Akuta N, Suzuki F, Hirakawa M, et al,. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 52: 421-429.
17. Furusyo N, Ogawa E, Nakamuta M, et al,. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol 2013; 59: 205-212.
18. Kawakami Y, Suzuki F, Karino Y, Toyota J, Kumada H, Chayama K,. Telaprevir is effective given every 12 hours at 750 mg with peginterferon-alfa-2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT. Antivir Ther 2014; 19: 277-285.
19. Zeuzem S, Berg T, Gane E, et al,. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014; 146: 430-441.